Why the study?
Following demonstrated 12-month non-inferiority of the biodegradable-polymer sirolimus-eluting stent compared to a durable-polymer everolimus-eluting stent, long-term 5-year clinical outcomes remained to be reported.
Does a biodegradable-polymer sirolimus-eluting stent improve target lesion failure compared to a durable-polymer everolimus-eluting stent in patients requiring PCI for myocardial ischaemia?
Does a biodegradable-polymer sirolimus-eluting stent improve target lesion failure compared to a durable-polymer everolimus-eluting stent in patients requiring PCI for myocardial ischaemia?
Answers are grounded in this paper and cite their sources.
The biodegradable-polymer sirolimus-eluting stent showed sustained non-inferiority to the durable-polymer everolimus-eluting stent for target lesion failure at 5 years in an all-comers PCI population.
BACKGROUND: In the prospective, multicentre, randomised TARGET All Comers study, percutaneous coronary intervention (PCI) with the FIREHAWK biodegradable-polymer sirolimus-eluting stent (BP-SES) was non-inferior to the durable-polymer everolimus-eluting stent (DP-EES) for the primary endpoint of target lesion failure (TLF) at 12 months. AIMS: We aimed to report the final study outcomes at 5 years. METHODS: Patients referred for PCI were randomised to receive either a BP-SES or DP-EES in a 1:1 ratio in 10 European countries. Randomisation was stratified by centre and ST-elevation myocardial infarction (STEMI) presentation, and clinical follow-up extended to 5 years. The primary endpoint was TLF (composite of cardiac death, target vessel myocardial infarction [MI], or ischaemia-driven target lesion revascularisation). Secondary endpoints included patient-oriented composite events (POCE; composite of all-cause death, all MI, or any revascularisation and its components). RESULTS: From December 2015 to October 2016, 1,653 patients were randomly assigned to the BP-SES or DP-EES groups, of which 93.8% completed 5-year clinical follow-up or were deceased. At 5 years, TLF occurred in 17.1% of the BP-SES group and in 16.3% of the DP-EES group (p=0.68). POCE occurred in 34.0% of the BP-SES group and 32.7% of the DP-EES group (p=0.58). Revascularisation was the most common POCE, occurring in 19.3% of patients receiving BP-SES and 19.2% receiving DP-EES, of which less than one-third was ischaemia-driven target lesion-related. In the landmark analysis, there were no differences in the rates of TLF and POCE between groups from 1 to 5 years, and these results were consistent across all subgroups. CONCLUSIONS: In an all-comers population requiring stent implantation for myocardial ischaemia, the BP-SES was non-inferior to the DP-EES for the primary endpoint of TLF at 12 months, and results were sustained at 5 years, confirming the long-term safety and efficacy of the FIREHAWK BP-SES.
No takes yet. Share an insight, caveat, or question.
Lansky et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: